Favorable Response of Advanced Superior Sulcus Non-Small Cell Lung Carcinoma to Gefitinib for 11 years complicated by Interval Development of Small Cell Carcinoma of the Lung

Favorable Response of Advanced Superior Sulcus Non-Small Cell Lung Carcinoma to Gefitinib for 11 years complicated by Interval Development of Small Cell Carcinoma of the Lung

Gefitinib is a medication that was originally developed as an epidermal growth factor receptor (EGFR) blocker. It has been used to treat non-small cell lung cancer with varying success. We describe a patient who presented with Pancoasts syndrome and after being deemed surgically unresectable had lim...

Full description

Bibliographic Details
Main Author: Mark H. Cooper
Format: Article
Language:English
Published: Marshall University 2018-01-01
Series:Marshall Journal of Medicine
Subjects:
Gefitinib
Lung cancer
Online Access:https://mds.marshall.edu/cgi/viewcontent.cgi?article=1158&context=mjm

Similar Items

Similar Items